FDA Approves New Treatment for Uncomplicated UTIs: Daily Dose
Your daily dose of the clinical news you may have missed.
GoodRx, Opill Team Up on OTC Delivery Program for Contraceptive
The new e-commerce partnership expands access to Opill by allowing direct delivery of the contraceptive to consumers' homes without a prescription.
Eisai Announces Completion of Rolling BLA for SQ Autoinjector-Delivered Lecanemab
The autoinjector delivers a weekly maintenance dose of 360 mg lecanemab for individuals who have completed biweekly treatment initiation by IV infusion.
Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.
Dermatologist Mona Shahriari, MD, Talks Nonsteroidal Topicals for Atopic Dermatitis
There are 3 classes of nonsteroidal topical therapies for atopic dermatitis that target the specific underlying pathophysiology of the skin disease. Shahriari provides a primer.
Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose
Greatest Increase in Mortality from Early-Onset Colorectal Cancer Seen Among Youngest US Adults
ACG: Mortality associated with both early- and late-stage EO-CRC rose most significantly among young adults aged 20 to 44 years between 2000 and 2022, new research reveals.
Worst States for Health Care in the US: 2024
Get a quick look at the US worst states for health care ranked using a composite score that included measures of cost, access, and outcomes.
GLP-1RAs Reduce the Risk of Early-Onset Colorectal Cancer in Adults with T2D
ACG 2024: New study results indicate GLP-1 RAs have a potentially protective role to play in combating EO-CRC, the incidence of which is notably rising worldwide.
New Phase 3 Data Suggest Benefits of Early Lecanemab Initiation on Alzheimer Disease Progression, Support Long-Term Safety
New data from phase 3 Clarity AD OLE trial show sustained treatment benefit among participants with low baseline tau and brain amyloid with no new safety signals.
Roche Amyloid Plasma Panel for Alzheimer Disease Demonstrates Negative Predictive Value of 96%, Company Announced
CATD 2024: The Elecsys plasma panel also demonstrated high sensitivity and specificity for AD, building strong evidence for streamlined early disease detection.
Social, Racial Disparities in Flu, COVID-19, RSV Vaccine Uptake: Daily Dose
Atopic Dermatitis: Final ADORING 3 Open-Label Extension Trial Findings with Tapinarof Cream, 1% Announced
Over 80% of participants, (2 to 17 y/o) achieved clear or almost clear skin during the 48-week trial, and treatment-free intervals lasted more than 2 months.
Early Detection of Skin Cancer Will Keep Getting Better Using AI-Based Technology: Expert Perspective
Rebecca Hartman, MD, MHP, assistant professor of dermatology at Brigham and Women's Hospital and Harvard Medical School, reviews new point-of-care detection technology.
Topical Steroids Still Have a Role in Atopic Dermatitis Treatment, But It is Limited Expert Says
Topical corticosteroids, once revolutionary for treatment of atopic dermatitis, are used just sparingly today; dermatologist Mona Shahriari, MD, lists the reasons.
Modified Donanemab Dosing Reduces ARIA-E in Adults with Early Symptomatic Alzheimer Disease
New phase 3b data suggest that a modified titration of donanemab reduces the risk of brain swelling and fluid accumulation at 24 weeks.
Pneumococcal 21-Valent Conjugate Vaccine in At-Risk Adults: Daily Dose
A Skin Cancer Triage Tool for Primary Care: One Specialist's Take on the DermaSensor Device
Dermatologist Rebecca Hartman, MD, MPH, said that reliable point-of-care screening results can help reduce unnecessary specialist referral for benign lesions.
Dermatologist Mona Shahriari, MD, Relies on Primary Care Colleagues as First-Line Prescribers for AD
Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.
Investigational RSV Vaccine Yields Positive Preliminary Data in Head-to-Head Comparison with Arexvy
Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.
